| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Propanolamines | 10 | 2021 | 70 | 2.570 |
Why?
|
| Acid Ceramidase | 10 | 2020 | 85 | 2.450 |
Why?
|
| Sphingolipids | 9 | 2021 | 337 | 1.870 |
Why?
|
| Amides | 6 | 2021 | 86 | 1.750 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 1070 | 1.460 |
Why?
|
| Prodrugs | 3 | 2017 | 54 | 1.270 |
Why?
|
| Enzyme Inhibitors | 8 | 2018 | 659 | 1.140 |
Why?
|
| Nitrobenzenes | 2 | 2017 | 13 | 1.080 |
Why?
|
| Ceramides | 12 | 2019 | 578 | 0.710 |
Why?
|
| Acetates | 1 | 2018 | 74 | 0.620 |
Why?
|
| Amines | 1 | 2018 | 98 | 0.600 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 629 | 0.600 |
Why?
|
| Head and Neck Neoplasms | 3 | 2019 | 561 | 0.530 |
Why?
|
| Drug Design | 2 | 2014 | 107 | 0.520 |
Why?
|
| Dextran Sulfate | 2 | 2017 | 88 | 0.490 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.490 |
Why?
|
| Apyrase | 1 | 2014 | 10 | 0.490 |
Why?
|
| Mucous Membrane | 1 | 2014 | 66 | 0.480 |
Why?
|
| Crohn Disease | 1 | 2014 | 38 | 0.470 |
Why?
|
| MCF-7 Cells | 3 | 2021 | 80 | 0.460 |
Why?
|
| Antigens, CD | 1 | 2014 | 230 | 0.450 |
Why?
|
| Colitis | 2 | 2017 | 156 | 0.450 |
Why?
|
| Th17 Cells | 1 | 2014 | 116 | 0.450 |
Why?
|
| Structure-Activity Relationship | 6 | 2021 | 420 | 0.430 |
Why?
|
| Molecular Structure | 5 | 2021 | 397 | 0.400 |
Why?
|
| Tumor Cells, Cultured | 4 | 2021 | 852 | 0.390 |
Why?
|
| Prostatic Neoplasms | 5 | 2019 | 778 | 0.370 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2010 | 240 | 0.360 |
Why?
|
| Cell Survival | 5 | 2021 | 901 | 0.360 |
Why?
|
| Sphingosine | 6 | 2019 | 315 | 0.360 |
Why?
|
| Ribonucleotides | 1 | 2010 | 26 | 0.360 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2010 | 25 | 0.350 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 1536 | 0.350 |
Why?
|
| Cell Line, Tumor | 11 | 2019 | 1851 | 0.350 |
Why?
|
| Isoenzymes | 4 | 2004 | 308 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 1745 | 0.320 |
Why?
|
| Apoptosis | 7 | 2017 | 1641 | 0.310 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 4 | 2017 | 201 | 0.310 |
Why?
|
| Cell Proliferation | 5 | 2021 | 1174 | 0.310 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2004 | 73 | 0.300 |
Why?
|
| Bridged-Ring Compounds | 2 | 2004 | 14 | 0.290 |
Why?
|
| Thiones | 2 | 2004 | 16 | 0.290 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 362 | 0.280 |
Why?
|
| Lysosomes | 2 | 2016 | 136 | 0.250 |
Why?
|
| Indoles | 3 | 2013 | 146 | 0.250 |
Why?
|
| Stereoisomerism | 4 | 2021 | 169 | 0.240 |
Why?
|
| Autophagy | 3 | 2017 | 208 | 0.240 |
Why?
|
| Humans | 26 | 2021 | 68618 | 0.240 |
Why?
|
| Oxidoreductases | 2 | 2015 | 117 | 0.230 |
Why?
|
| Mice, Nude | 4 | 2019 | 294 | 0.220 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 111 | 0.220 |
Why?
|
| Pyridinium Compounds | 2 | 2014 | 40 | 0.210 |
Why?
|
| Mice | 15 | 2020 | 8474 | 0.200 |
Why?
|
| Photochemotherapy | 2 | 2013 | 59 | 0.200 |
Why?
|
| Lysophospholipids | 3 | 2019 | 209 | 0.200 |
Why?
|
| Animals | 17 | 2020 | 20881 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 299 | 0.200 |
Why?
|
| Arthritis, Experimental | 2 | 2020 | 38 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2013 | 35 | 0.190 |
Why?
|
| Heterocyclic Compounds | 1 | 2001 | 24 | 0.190 |
Why?
|
| Adamantane | 2 | 2017 | 40 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 77 | 0.180 |
Why?
|
| Antigen Presentation | 1 | 2020 | 76 | 0.180 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2004 | 73 | 0.170 |
Why?
|
| Myristates | 3 | 2008 | 21 | 0.170 |
Why?
|
| Palmitates | 1 | 2019 | 20 | 0.170 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 122 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 186 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 139 | 0.160 |
Why?
|
| src-Family Kinases | 1 | 2019 | 91 | 0.160 |
Why?
|
| Pyridines | 2 | 2017 | 261 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 381 | 0.160 |
Why?
|
| Myristic Acid | 1 | 2017 | 6 | 0.150 |
Why?
|
| Enzyme Activation | 4 | 2016 | 791 | 0.150 |
Why?
|
| Phosphotransferases | 1 | 2017 | 16 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2016 | 2689 | 0.150 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2017 | 26 | 0.150 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 24 | 0.150 |
Why?
|
| Acyltransferases | 1 | 2017 | 40 | 0.150 |
Why?
|
| Guanidines | 1 | 2017 | 32 | 0.150 |
Why?
|
| Cathepsin D | 1 | 2016 | 13 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2017 | 62 | 0.140 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 21 | 0.140 |
Why?
|
| Cathepsin B | 1 | 2016 | 33 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2017 | 260 | 0.140 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2015 | 140 | 0.140 |
Why?
|
| Sarcoma | 1 | 2016 | 70 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 99 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 6 | 2019 | 2791 | 0.130 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2015 | 7 | 0.130 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 38 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 284 | 0.130 |
Why?
|
| Esters | 1 | 2014 | 22 | 0.120 |
Why?
|
| Membrane Proteins | 4 | 2015 | 617 | 0.120 |
Why?
|
| Time Factors | 3 | 2018 | 4655 | 0.120 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2015 | 62 | 0.120 |
Why?
|
| Protein Binding | 2 | 2014 | 1027 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 86 | 0.120 |
Why?
|
| HeLa Cells | 1 | 2014 | 237 | 0.120 |
Why?
|
| Caspase 3 | 2 | 2013 | 233 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2014 | 62 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 40 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2015 | 489 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 95 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2015 | 682 | 0.110 |
Why?
|
| Mice, SCID | 3 | 2019 | 238 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 710 | 0.110 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2014 | 183 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2013 | 178 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2015 | 954 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 756 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.100 |
Why?
|
| Disease Progression | 4 | 2019 | 1038 | 0.100 |
Why?
|
| Photosensitizing Agents | 1 | 2011 | 32 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 446 | 0.090 |
Why?
|
| Amidohydrolases | 2 | 2007 | 60 | 0.090 |
Why?
|
| U937 Cells | 3 | 2004 | 61 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 332 | 0.090 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2010 | 93 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 4 | 2004 | 160 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2010 | 101 | 0.080 |
Why?
|
| Monocytes | 1 | 2010 | 210 | 0.080 |
Why?
|
| Female | 4 | 2017 | 38074 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 73 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2010 | 258 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 507 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 658 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2004 | 46 | 0.080 |
Why?
|
| Norbornanes | 2 | 2004 | 8 | 0.070 |
Why?
|
| Male | 10 | 2019 | 37321 | 0.070 |
Why?
|
| Thiocarbamates | 2 | 2004 | 20 | 0.070 |
Why?
|
| Galactosylgalactosylglucosylceramidase | 1 | 2007 | 39 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2019 | 326 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2014 | 304 | 0.070 |
Why?
|
| Busulfan | 1 | 2006 | 13 | 0.070 |
Why?
|
| Pyrroles | 2 | 2004 | 83 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 57 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 514 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 134 | 0.070 |
Why?
|
| Cytokines | 1 | 2010 | 866 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2006 | 112 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 175 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1330 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 231 | 0.060 |
Why?
|
| Esterases | 1 | 2004 | 9 | 0.060 |
Why?
|
| Sulfides | 1 | 2004 | 43 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 532 | 0.060 |
Why?
|
| Drug Stability | 1 | 2004 | 71 | 0.060 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2004 | 9 | 0.060 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2004 | 15 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2004 | 144 | 0.060 |
Why?
|
| RNA Interference | 2 | 2015 | 266 | 0.060 |
Why?
|
| Leukemia | 1 | 2004 | 117 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2015 | 1664 | 0.060 |
Why?
|
| Macrophages, Peritoneal | 1 | 2002 | 67 | 0.050 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2001 | 16 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2001 | 128 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2017 | 2673 | 0.050 |
Why?
|
| HLA-DR4 Antigen | 1 | 2020 | 11 | 0.050 |
Why?
|
| Macrophages | 2 | 2020 | 647 | 0.050 |
Why?
|
| Cathepsins | 1 | 2020 | 37 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 120 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
| Cyclooxygenase 1 | 3 | 2004 | 29 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 70 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 81 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Aged | 1 | 2014 | 14862 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 329 | 0.040 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2007 | 25 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 235 | 0.040 |
Why?
|
| Ceramidases | 2 | 2007 | 47 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 137 | 0.040 |
Why?
|
| Chemokine CXCL2 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2017 | 351 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 21 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 50 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2017 | 112 | 0.040 |
Why?
|
| Middle Aged | 1 | 2014 | 21147 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 194 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 1752 | 0.030 |
Why?
|
| Adult | 1 | 2014 | 21403 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 160 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 138 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2015 | 77 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 130 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1200 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 626 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 17 | 0.030 |
Why?
|
| Annexin A5 | 1 | 2013 | 16 | 0.030 |
Why?
|
| fas Receptor | 1 | 2014 | 54 | 0.030 |
Why?
|
| Propidium | 1 | 2013 | 26 | 0.030 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2013 | 24 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2013 | 31 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 22 | 0.030 |
Why?
|
| Dasatinib | 1 | 2013 | 17 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 134 | 0.030 |
Why?
|
| Edema | 2 | 2004 | 66 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 119 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 89 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 195 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 226 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 782 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 615 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 770 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 331 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 346 | 0.020 |
Why?
|
| Mitochondria | 1 | 2013 | 643 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 140 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 5300 | 0.020 |
Why?
|
| DNA Damage | 1 | 2006 | 190 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 247 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.020 |
Why?
|
| Cell Movement | 1 | 2007 | 630 | 0.010 |
Why?
|
| Cytotoxins | 1 | 2004 | 23 | 0.010 |
Why?
|
| Diglycerides | 1 | 2004 | 49 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2004 | 138 | 0.010 |
Why?
|
| Carrageenan | 1 | 2003 | 7 | 0.010 |
Why?
|
| Reaction Time | 1 | 2004 | 170 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 371 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 63 | 0.010 |
Why?
|
| Foot | 1 | 2003 | 66 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 270 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 447 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 902 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 2083 | 0.010 |
Why?
|